Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 8 | 2019 | 904 | 1.700 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1763 | 1.100 |
Why?
|
| Dendritic Cells | 8 | 2011 | 1085 | 1.100 |
Why?
|
| CD40 Antigens | 3 | 2011 | 104 | 0.730 |
Why?
|
| Chemokine CCL5 | 2 | 2010 | 71 | 0.700 |
Why?
|
| Cancer Vaccines | 6 | 2011 | 697 | 0.690 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 577 | 0.610 |
Why?
|
| Transduction, Genetic | 3 | 2016 | 475 | 0.600 |
Why?
|
| K562 Cells | 3 | 2019 | 338 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2019 | 1146 | 0.570 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 3869 | 0.550 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 598 | 0.530 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 895 | 0.430 |
Why?
|
| Oncolytic Viruses | 2 | 2009 | 204 | 0.360 |
Why?
|
| Adenoviridae | 5 | 2019 | 1459 | 0.310 |
Why?
|
| Cell Proliferation | 4 | 2016 | 7226 | 0.310 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 657 | 0.300 |
Why?
|
| Neoplasms | 5 | 2022 | 15193 | 0.280 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 203 | 0.280 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 2796 | 0.270 |
Why?
|
| Genetic Vectors | 4 | 2019 | 1694 | 0.260 |
Why?
|
| Cell Movement | 2 | 2010 | 2466 | 0.240 |
Why?
|
| Blood Component Removal | 2 | 2016 | 121 | 0.240 |
Why?
|
| Multiple Myeloma | 1 | 2015 | 2138 | 0.230 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 269 | 0.220 |
Why?
|
| Lymphocyte Activation | 4 | 2017 | 1688 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 582 | 0.210 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1616 | 0.210 |
Why?
|
| Flow Cytometry | 4 | 2017 | 3033 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 1586 | 0.200 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 361 | 0.190 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2011 | 15 | 0.180 |
Why?
|
| Immunotherapy | 3 | 2010 | 3341 | 0.180 |
Why?
|
| Cell Transplantation | 2 | 2017 | 85 | 0.170 |
Why?
|
| Interleukin-12 | 3 | 2011 | 253 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1489 | 0.170 |
Why?
|
| Retroviridae | 1 | 2019 | 332 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.170 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 2216 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 100 | 0.160 |
Why?
|
| CD28 Antigens | 1 | 2017 | 202 | 0.140 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 558 | 0.140 |
Why?
|
| CD3 Complex | 1 | 2017 | 314 | 0.140 |
Why?
|
| Feeder Cells | 1 | 2016 | 13 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2015 | 3536 | 0.140 |
Why?
|
| Interleukin-15 | 2 | 2017 | 185 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 966 | 0.130 |
Why?
|
| Humans | 23 | 2024 | 261506 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 6550 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 5112 | 0.120 |
Why?
|
| Cell Differentiation | 5 | 2017 | 4078 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 2314 | 0.120 |
Why?
|
| Cell Survival | 2 | 2012 | 3045 | 0.110 |
Why?
|
| Leukemia | 1 | 2022 | 1635 | 0.110 |
Why?
|
| Organic Chemicals | 2 | 2011 | 113 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 284 | 0.110 |
Why?
|
| 4-1BB Ligand | 1 | 2012 | 15 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2011 | 32 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 54 | 0.100 |
Why?
|
| Mice | 9 | 2019 | 34495 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 175 | 0.100 |
Why?
|
| Animals | 11 | 2019 | 59536 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 235 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 62 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2011 | 54 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 2638 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 7548 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1870 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2019 | 675 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2006 | 2074 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2011 | 155 | 0.090 |
Why?
|
| beta-Defensins | 1 | 2009 | 30 | 0.090 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2009 | 22 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2010 | 138 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 14551 | 0.090 |
Why?
|
| COS Cells | 1 | 2009 | 377 | 0.080 |
Why?
|
| Ovalbumin | 1 | 2009 | 254 | 0.080 |
Why?
|
| Cytokines | 2 | 2017 | 2809 | 0.080 |
Why?
|
| Tumor Escape | 1 | 2010 | 251 | 0.080 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 1082 | 0.080 |
Why?
|
| Receptors, CCR7 | 1 | 2007 | 39 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 14289 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2011 | 6942 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2007 | 295 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1732 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2007 | 208 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2007 | 250 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2014 | 1869 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2011 | 1529 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2009 | 280 | 0.070 |
Why?
|
| Child | 3 | 2022 | 29154 | 0.060 |
Why?
|
| Cell Line | 2 | 2011 | 5114 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2017 | 842 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2019 | 16273 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 1038 | 0.060 |
Why?
|
| Centrifugation | 1 | 2022 | 66 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 1016 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 10035 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2005 | 1008 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2005 | 837 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2017 | 1681 | 0.050 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 15694 | 0.050 |
Why?
|
| Female | 7 | 2019 | 141928 | 0.050 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 174 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 1678 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2054 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 56 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1819 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 6295 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Risk Factors | 1 | 2015 | 17523 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 6915 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 314 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 5395 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2017 | 95 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 188 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3981 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2011 | 11965 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 995 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2011 | 5710 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 2843 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 71 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 107 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2011 | 1549 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 32848 | 0.030 |
Why?
|
| Recurrence | 1 | 2022 | 4758 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 394 | 0.030 |
Why?
|
| Disease Progression | 1 | 2005 | 6682 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 1555 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2014 | 201 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2014 | 272 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 219 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 686 | 0.030 |
Why?
|
| Aged | 2 | 2017 | 70117 | 0.030 |
Why?
|
| Male | 4 | 2017 | 123000 | 0.030 |
Why?
|
| Apoptosis | 1 | 2006 | 7591 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2014 | 471 | 0.030 |
Why?
|
| Lymphoma | 2 | 2014 | 1467 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2011 | 22 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 905 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 105 | 0.030 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2014 | 323 | 0.030 |
Why?
|
| Middle Aged | 2 | 2017 | 86204 | 0.030 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2011 | 22 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 119 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2011 | 100 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 279 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 246 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 931 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 375 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 362 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 8873 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 368 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 2864 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 1479 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 1313 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 750 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 14889 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2006 | 14 | 0.020 |
Why?
|
| Biosynthetic Pathways | 1 | 2006 | 46 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1070 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 1489 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 77950 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 3438 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 369 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4143 | 0.010 |
Why?
|
| Carcinoma | 1 | 2014 | 2578 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5637 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 37905 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 29902 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 5767 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4654 | 0.010 |
Why?
|
| Melanoma | 1 | 2006 | 5317 | 0.010 |
Why?
|